Available to mentor
Dr. Suresh is a Research Assistant Professor in the division of Biostatistics and Bioinformatics in the Department of Radiation Oncology. She also has a joint appointment as a Research Assistant Professor of Biostatistics. Her research interests include survival analysis, longitudinal data, joint modeling, and prediction models, with applications in cancer research and other health outcomes.
-
Masters of MathematicsUniversity of Waterloo, Waterloo, 2103
-
PhD, BiostatisticsUniversity of Michigan, Ann Arbor, 2018
-
Bachelor of Honours MathematicsUniversity of Waterloo, Waterloo, 2012
-
Bachelor of Business AdministrationWilfrid Laurier University, Waterloo, 2012
-
Center MemberRogel Cancer Center
1. Developing prediction models for personalized medicine: I have developed methods that incorporate changing patient information, such as longitudinally collected biomarkers, to produce dynamic risk predictions during a patient’s follow-up.
2. Statistical analysis of outcomes in cancer research: My work in this area includes identifying important predictors of time-to-event and binary outcomes, propensity-score methods for analyzing observational data, and modelling longitudinal data.
3. Clinical trial design and analysis: I am the lead biostatistician on several randomized clinical study designs that study community- or clinic-based interventions for a variety of health outcomes.
-
Suresh K. 2024 Nov 22;PresentationA Comparison of Natural Histories from Three Microsimulations
-
Suresh K. 2024 Nov 19;PresentationPatient Reported Outcomes for Predicting Cancer Recurrence
-
Edwards DM, Gharzai LA, Wang W, Mayo C, Suresh K, Schipper M, Evans JR, Malloy K, Chinn SB, Prince M, Spector M, Shuman A, Stucken C, Swiecicki PL, Worden F, Jarema J, Henderson C, Kovach A, Brenner C, Shah JL, Mierzwa ML, Casper K. Head Neck, 2024 Nov; 46 (11): 2687 - 2698.Journal ArticleFollow-up for human papillomavirus-related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient-reported outcome collection.
DOI:10.1002/hed.27778 PMID: 38680087 -
Suresh K. 2024 Nov 1;PresentationModeling Prostate Cancer: A Microsimulation Study
-
Umemura Y, Clarke N, Al-Holou W, Elaimy AL, Scott A, Leung D, Kim M, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Neuro-Oncology, 2024 Oct 17; 26 (Supplement_5): v98 - v98.Journal ArticleP18.13.A DE-NOVO PURINE METABOLISM CAN BE TARGETED SAFELY IN GLIOBLASTOMA TREATMENT TO OVERCOME CHEMORADIATION RESISTANCE: AN INTERIM RESULT OF PHASE 0/1 CLINICAL TRIAL
DOI:10.1093/neuonc/noae144.329 -
Regan SN, Aryal MP, Suresh K, Rosen BS, Walline H, Prince ME, Malloy K, Casper K, Shuman A, Chinn SB, Heft-Neal ME, Swiecicki PL, Worden F, Shah JL, Cao Y, Brenner C, Mierzwa ML. International Journal of Radiation Oncology • Biology • Physics, 2024 Oct; 120 (2): s131Proceeding / Abstract / PosterImaging Metrics and HPV ctDNA Kinetics in a Phase II Immuno-Chemoradiation Trial for Locoregionally Advanced p16+ Oropharynx Cancer
DOI:10.1016/j.ijrobp.2024.07.238 -
Umemura Y, Clarke N, Al-Holou W, Elaimy A, Scott A, Leung D, Kim M, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Chin Clin Oncol, 2024 Aug; 13 (Suppl 1): AB036Journal ArticleAB036. Targeting glioblastoma de-novo purine metabolism to overcome chemoradiation resistance: an interim result of phase 0/1 clinical trial in newly diagnosed and recurrent glioblastoma.
DOI:10.21037/cco-24-ab036 PMID: 39295354 -
Brewer SE, Bertin KB, Suresh K, LoudHawk-Hedgepeth C, Tamez M, Reno JE, Kwan BM, Nease DE. PLoS One, 2024 19 (6): e0305160Journal ArticleFactors in COVID-19 vaccine uptake in five racial/ethnic Colorado communities: A report from the Colorado CEAL project.
DOI:10.1371/journal.pone.0305160 PMID: 38865424